Immunological Medicine最新文献_第2页

Neurologic immune-related adverse events from immune checkpoint inhibitors: recent advances and future prospectives. 免疫检查点抑制剂的神经免疫相关不良事件：最新进展和未来展望

IF 2.3

Immunological Medicine Pub Date : 2026-09-01 Epub Date: 2026-05-30 DOI: 10.1080/25785826.2026.2680741

Tomoya Kawazoe, Akihito Hao, Shigeaki Suzuki

{"title":"Neurologic immune-related adverse events from immune checkpoint inhibitors: recent advances and future prospectives.","authors":"Tomoya Kawazoe, Akihito Hao, Shigeaki Suzuki","doi":"10.1080/25785826.2026.2680741","DOIUrl":"10.1080/25785826.2026.2680741","url":null,"abstract":"Immune checkpoint inhibitors (ICI) have transformed cancer therapy but can disrupt immune tolerance, causing immune-related adverse events (irAE) in various organs. ICI-induced neurological irAE encompass a heterogeneous spectrum of central and peripheral nervous system disorders. A recently proposed diagnostic algorithm recommends first excluding alternative etiologies, then confirming neuroinflammation using laboratory or radiological evidence. The clinical presentation of neurological irAE is often atypical and may go unrecognized in routine practice, and the impact of irAE on morbidity and mortality is disproportionately high, particularly in phenotypes with overlapping cardiac or respiratory involvement. These facts, along with the early onset, rapid progression, and frequent corticosteroid-refractoriness characteristic of many neurological irAE, underscore the need for heightened clinical vigilance and rapid initiation of immunomodulatory therapy. Targeted biologics are also under active investigation in response to the growing recognition of corticosteroid-refractory neurological irAE. Triple M syndrome-the concurrent occurrence of ICI-induced myasthenia, myositis, and myocarditis-represents the most severe and life-threatening irAE. Certain high-risk populations, including patients with pre-existing neurological autoimmune diseases, thymoma, or paraneoplastic neurologic syndromes, may be predisposed to this and other severe neurological irAE. Future research should focus on refining predictive biomarkers, including autoantibody profiles, cytokine signatures, and neuro-injury markers.","PeriodicalId":37286,"journal":{"name":"Immunological Medicine","volume":" ","pages":"334-345"},"PeriodicalIF":2.3,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148057334","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Immune checkpoint inhibitor-associated hepatitis and colitis: current understanding and clinical approaches. 免疫检查点抑制剂相关肝炎和结肠炎：目前的认识和临床方法

IF 2.3

Immunological Medicine Pub Date : 2026-09-01 Epub Date: 2026-06-02 DOI: 10.1080/25785826.2026.2679874

Yuta Myojin, Takahiro Kodama

{"title":"Immune checkpoint inhibitor-associated hepatitis and colitis: current understanding and clinical approaches.","authors":"Yuta Myojin, Takahiro Kodama","doi":"10.1080/25785826.2026.2679874","DOIUrl":"10.1080/25785826.2026.2679874","url":null,"abstract":"Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment by harnessing the immune system to target tumors. The introduction of ipilimumab, an anti-CTLA-4 monoclonal antibody, marked a major milestone in immuno-oncology when it was approved by the U.S. Food and Drug Administration (FDA) in 2011 for advanced melanoma. By blocking CTLA-4, ipilimumab enhances T-cell activation and promotes antitumor immunity. Subsequent development and approval of anti-PD-1 and anti-PD-L1 antibodies, such as nivolumab and pembrolizumab, since 2014 have broadened the scope of ICI therapy to various malignancies, often demonstrating improved tolerability relative to CTLA-4 inhibition. While these agents have significantly improved clinical outcomes, they also disrupt immune homeostasis, leading to immune-related adverse events (irAEs), in which healthy tissues are attacked by the immune system. Among these, gastrointestinal irAEs - including hepatitis and colitis - are frequently observed and may require intensive management. These toxicities are immunologically mediated and differ substantially from adverse effects associated with conventional cytotoxic chemotherapy. As ICIs gain broader indications clinicians must be prepared to identify and manage irAEs promptly. This review provides an in-depth discussion of ICI-associated gastrointestinal toxicities, emphasizing their epidemiology, immunopathogenesis, diagnostic strategies, and therapeutic management, in line with the latest clinical guidelines from major oncological societies such as ASCO and ESMO.","PeriodicalId":37286,"journal":{"name":"Immunological Medicine","volume":" ","pages":"304-316"},"PeriodicalIF":2.3,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148151000","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cutaneous adverse events due to immune checkpoint inhibitors. 免疫检查点抑制剂引起的皮肤不良事件。

IF 2.3

Immunological Medicine Pub Date : 2026-09-01 Epub Date: 2026-07-09 DOI: 10.1080/25785826.2026.2699471

Takafumi Kadono, Tomomitsu Miyagaki

引用次数: 0

Immunopathophysiology of immune checkpoint inhibitor-related pneumonitis: insights from multi-omics and immune profiling. 免疫检查点抑制剂相关肺炎的免疫病理生理学：来自多组学和免疫谱分析的见解。

IF 2.3

Immunological Medicine Pub Date : 2026-09-01 Epub Date: 2026-05-18 DOI: 10.1080/25785826.2026.2674327

Sumiyuki Nishida, Takayuki Shiroyama, Yujiro Naito, Atsushi Kumanogoh

{"title":"Immunopathophysiology of immune checkpoint inhibitor-related pneumonitis: insights from multi-omics and immune profiling.","authors":"Sumiyuki Nishida, Takayuki Shiroyama, Yujiro Naito, Atsushi Kumanogoh","doi":"10.1080/25785826.2026.2674327","DOIUrl":"10.1080/25785826.2026.2674327","url":null,"abstract":"Although immune checkpoint inhibitors (ICIs) have demonstrated groundbreaking effectiveness in cancer treatment, they carry the risk of immune-related adverse events, including interstitial pneumonia (ICI-pneumonitis), a potentially life-threatening pulmonary complication. Comprehensive immune analyses of peripheral blood, bronchoalveolar lavage fluid, and lung tissue have demonstrated that ICI-pneumonitis results from excessive activation and proliferation of cytotoxic T lymphocytes and helper T cells, suppression of regulatory T cells, and increased secretion of pro-inflammatory cytokines. The dysregulation of innate immune cells also contributes to the formation of a complex immune microenvironment. Bronchoalveolar lavage fluid analyses revealed a lymphocyte-rich cell population dominated by CD8+ T cells and CD4+ types 1 and 17 helper T cells. Studies on lung tissues using spatial transcriptomics and imaging mass cytometry have provided detailed insights into the inflammatory microenvironment. These studies enhance our understanding of the intricate relationships between immune cells and the mechanisms underlying pulmonary tissue injury. Integrating multi-omics data will provide new insights into the immuno-pathophysiology of ICI-pneumonitis, deepening our understanding of this condition. These insights will enable more precise individual risk assessments and facilitate the development of safer immunotherapeutic strategies. This review highlights the recent research findings and provides an overview of the immunopathophysiology of ICI-pneumonitis.","PeriodicalId":37286,"journal":{"name":"Immunological Medicine","volume":" ","pages":"317-333"},"PeriodicalIF":2.3,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147964484","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Effect of organism aging on the development of anti-PD-(L)1 therapy-associated adverse events. 机体衰老对抗pd -(L)1治疗相关不良事件发展的影响。

IF 2.3

Immunological Medicine Pub Date : 2026-09-01 Epub Date: 2025-10-01 DOI: 10.1080/25785826.2025.2564474

Hirotake Tsukamoto, Kosaku Murakami, Yuji Miura, Yoshihiro Komohara

{"title":"Effect of organism aging on the development of anti-PD-(L)1 therapy-associated adverse events.","authors":"Hirotake Tsukamoto, Kosaku Murakami, Yuji Miura, Yoshihiro Komohara","doi":"10.1080/25785826.2025.2564474","DOIUrl":"10.1080/25785826.2025.2564474","url":null,"abstract":"Immune checkpoint inhibitor (ICI)-mediated release of immune suppression involves the risk of (re)activating the immune responses to self-tissues, which are considered 'side effects' of this therapy, immune-related adverse events (irAEs). Although the incidence of certain types of irAEs appears to be considerably increased in older patients, the effect of chronological aging on irAE development and their causative immunological mechanism are unclear. This review summarizes the potential relevance of chronological and cellular aging, such as age-associated changes in T-cell functions and aged environmental factors, and inflamm-aging, in shaping irAE-inducing immune responses. Several immunological perspectives on aging may provide insights into the practical consideration of the toxicity risks of ICIs, particularly in elderly patients. These insights from patient specimens and pre-clinical animal models will help establishing mechanism-based management strategies, including stratification of irAE-prone patients, and broadening the patient population that benefits from cancer immunotherapy, even in a younger population.","PeriodicalId":37286,"journal":{"name":"Immunological Medicine","volume":" ","pages":"290-303"},"PeriodicalIF":2.3,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145201737","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Three-body problems involving the mother, fetus, and microorganisms. 涉及母亲、胎儿和微生物的三体问题。

IF 2.3

Immunological Medicine Pub Date : 2026-08-28 DOI: 10.1080/25785826.2026.2722507

Satoshi Hayakawa, Gil Mor, Yoshihiko Araki, Shihoko Komine-Aizawa

{"title":"Three-body problems involving the mother, fetus, and microorganisms.","authors":"Satoshi Hayakawa, Gil Mor, Yoshihiko Araki, Shihoko Komine-Aizawa","doi":"10.1080/25785826.2026.2722507","DOIUrl":"https://doi.org/10.1080/25785826.2026.2722507","url":null,"abstract":"Pregnancy is a unique immunological state in which the maternal immune system tolerates a semi-allogeneic fetus. Traditionally, this relationship has been viewed as a dyadic interaction between the mother and the fetoplacental unit. However, accumulating evidence suggests that this paradigm is incomplete and that microorganisms, including those in the reproductive tract and gut microbiota, play crucial roles in modulating maternal-fetal immune balance. We propose that pregnancy should be reconsidered as a three-body framework comprising the maternal immune system, the fetoplacental unit, and microorganisms. This concept is derived from the classical three-body problem in celestial mechanics, in which the addition of a third interacting body results in complex and often unpredictable dynamics. Similarly, the maternal-fetal-microbial system exhibits nonlinear interactions, feedback loops, and sensitivity to initial conditions, which may underlie the heterogeneity of pregnancy outcomes. Microorganisms also interact with viral infections at the maternal-fetal interface and exert context-dependent effects on implantation, trophoblast invasion, immune regulation, and susceptibility to infection. Even minor perturbations within this system may lead to disproportionately large biological effects, analogous to the 'butterfly effect'. This framework provides a conceptual basis for understanding pregnancy and its associated disorders.","PeriodicalId":37286,"journal":{"name":"Immunological Medicine","volume":" ","pages":"1-8"},"PeriodicalIF":2.3,"publicationDate":"2026-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148841195","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Rheumatoid arthritis flares and de novo inflammatory arthritis after immune checkpoint inhibitor therapy: a single-center exploratory study of clinical phenotypes. 免疫检查点抑制剂治疗后类风湿关节炎发作和新发炎性关节炎：临床表型的单中心探索性研究

IF 2.3

Immunological Medicine Pub Date : 2026-08-28 DOI: 10.1080/25785826.2026.2722488

Shion Kachi, Mirei Shirakashi, Motoo Nomura, Yoichi Nakayama, Hirokazu Taguchi, Tsuneo Sasai, Ryosuke Hiwa, Hideaki Tsuji, Shuji Akizuki, Akira Onishi, Hajime Yoshifuji, Masao Tanaka, Ran Nakashima, Kosaku Murakami, Akio Morinobu

{"title":"Rheumatoid arthritis flares and de novo inflammatory arthritis after immune checkpoint inhibitor therapy: a single-center exploratory study of clinical phenotypes.","authors":"Shion Kachi, Mirei Shirakashi, Motoo Nomura, Yoichi Nakayama, Hirokazu Taguchi, Tsuneo Sasai, Ryosuke Hiwa, Hideaki Tsuji, Shuji Akizuki, Akira Onishi, Hajime Yoshifuji, Masao Tanaka, Ran Nakashima, Kosaku Murakami, Akio Morinobu","doi":"10.1080/25785826.2026.2722488","DOIUrl":"10.1080/25785826.2026.2722488","url":null,"abstract":"Immune checkpoint inhibitors (ICIs) can cause de novo inflammatory arthritis and flares of pre-existing rheumatoid arthritis (RA). This study aimed to describe and explore the clinical characteristics and treatment outcomes of these arthritis groups in a single-center, exploratory cohort. We retrospectively analyzed patients who developed inflammatory arthritis after ICI therapy, including pre-existing RA flares and the de novo cases. The de novo cases were operationally classified based on the 2010 ACR/EULAR classification criteria into those who fulfilled the criteria (ICI-RA) and those who did not (ICI-IA). Of 41 de novo cases, 10 and 31 patients were classified into ICI-RA and ICI-IA, respectively. Six patients with RA experienced flares. At baseline, serum IgA was numerically higher in the RA flare group than in the non-flare group (median 482.5 vs. 266 mg/dL). At onset, the ICI-IA group exhibited higher eosinophil counts than the RA flare group (median 140 vs. 7/µL), although prior glucocorticoid exposure may have influenced these values. At 365 days, cumulative treatment discontinuation rates were 34.1% for ICI-IA, 20.0% for ICI-RA, and 0% for RA flares. These operationally defined subgroups exhibited heterogeneous clinical courses. These hypothesis-generating findings support future prospective cohorts with detailed immunophenotyping.","PeriodicalId":37286,"journal":{"name":"Immunological Medicine","volume":" ","pages":"1-11"},"PeriodicalIF":2.3,"publicationDate":"2026-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148840996","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clonal hematopoiesis in immune-related and neurological disorders. 免疫相关和神经系统疾病的克隆造血。

IF 2.3

Immunological Medicine Pub Date : 2026-08-26 DOI: 10.1080/25785826.2026.2722467

Kotaro Ogawa, Tomohiro Yata, Yuto Hayashi, Tatsusada Okuno

引用次数: 0

MxA expression in systemic lupus erythematosus -associated myocarditis indicates type I interferon pathway activation. MxA在系统性红斑狼疮相关性心肌炎中的表达表明I型干扰素通路激活。

IF 2.3

Immunological Medicine Pub Date : 2026-08-24 DOI: 10.1080/25785826.2026.2722497

Yuhei Ito, Yoshiyuki Arinuma, Hiroto Yuasa, Keishi Moriwaki, Hiroshi Imai, Ayako Nakajima

{"title":"MxA expression in systemic lupus erythematosus -associated myocarditis indicates type I interferon pathway activation.","authors":"Yuhei Ito, Yoshiyuki Arinuma, Hiroto Yuasa, Keishi Moriwaki, Hiroshi Imai, Ayako Nakajima","doi":"10.1080/25785826.2026.2722497","DOIUrl":"https://doi.org/10.1080/25785826.2026.2722497","url":null,"abstract":"Type I interferon (IFN) pathway activation plays an important role in the pathogenesis of systemic lupus erythematosus (SLE). Myxovirus resistance protein A (MxA) is a surrogate marker of type I IFN activity; however, evidence of local IFN pathway activation in myocarditis associated with SLE remains limited. The first patient was a 51-year-old man with newly diagnosed SLE complicated by neuropsychiatric SLE, class IV lupus nephritis, erythema and myocarditis at presentation. The second patient was a 56-year-old woman with class V lupus nephritis who developed acute decompensated heart failure due to myocarditis approximately 4 months after the diagnosis of SLE. In both cases, cardiac magnetic resonance imaging and histopathological findings by endomyocardial biopsy like IgG and C1q deposition along myocardial vessel walls supported the diagnosis of myocarditis associated with SLE. Immunohistochemical staining demonstrated prominent MxA expression in cardiomyocytes in the first patient, while MxA-positive staining corresponding to CD34-positive vascular structures was observed in both patients. MxA staining was absent in control myocardial tissue from non-inflammatory dilated cardiomyopathy. These findings provide rare tissue-level evidence of MxA expression in biopsy-proven myocarditis associated with SLE resulted from local type I IFN pathway activation in this severe complication of SLE.","PeriodicalId":37286,"journal":{"name":"Immunological Medicine","volume":" ","pages":"1-6"},"PeriodicalIF":2.3,"publicationDate":"2026-08-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148809281","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pediatric Sweet syndrome initially misdiagnosed as immunoglobulin a vasculitis: the importance of repeat biopsy. 小儿甜综合征最初误诊为免疫球蛋白a血管炎：重复活检的重要性。

IF 2.3

Immunological Medicine Pub Date : 2026-08-22 DOI: 10.1080/25785826.2026.2722481

Shizuno Komatsu, Takuma Ito, Shutaro Suga, Reiji Fukano, Natsuko Sasaki, Yu Sawada

{"title":"Pediatric Sweet syndrome initially misdiagnosed as immunoglobulin a vasculitis: the importance of repeat biopsy.","authors":"Shizuno Komatsu, Takuma Ito, Shutaro Suga, Reiji Fukano, Natsuko Sasaki, Yu Sawada","doi":"10.1080/25785826.2026.2722481","DOIUrl":"https://doi.org/10.1080/25785826.2026.2722481","url":null,"abstract":"Sweet syndrome is characterized by tender erythematous plaques, histologically presenting as marked neutrophilic infiltration in the dermis. In general, this syndrome manifests in middle-aged adults, and given its extreme rarity in the pediatric population, it is rarely considered by pediatricians in routine clinical practice, which often leads to misdiagnosis. A 1-year-old girl had developed palpable purpura subsequent to experiencing upper respiratory symptoms, and at a previous hospital, she was preliminarily diagnosed with immunoglobulin A (IgA) vasculitis in the absence of skin biopsy evidence. The purpura developed into refractory hemorrhagic blisters and subsequently became ulcerated. Although intravenous glucocorticoid therapy was initiated, there was no discernable improvement. After being transferred to our hospital, she initially underwent a skin biopsy, which failed to lead to a diagnosis. We tapered the administration of intravenous glucocorticoid and performed a second skin biopsy, retrieving a specimen from a newly affected lesion. The histopathological findings for the second biopsy revealed marked neutrophilic infiltration extending from the dermis to the adipose tissue, with interstitial dermal edema, which met the diagnostic criteria of Sweet syndrome. This case highlights the importance of prioritizing early diagnostic biopsy prior to initiating empiric therapy when atypical cutaneous features are observed in suspected individuals.","PeriodicalId":37286,"journal":{"name":"Immunological Medicine","volume":" ","pages":"1-7"},"PeriodicalIF":2.3,"publicationDate":"2026-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148799116","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0